Roseola medical therapy: Difference between revisions
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
There is no treatment for roseola, however intravenous Foscarnet and ganciclovir are proposed as first line treatment for HHV 6 encephalitis for 3 to 4 weeks.<ref name="pmid25762531">{{cite journal| author=Agut H, Bonnafous P, Gautheret-Dejean A| title=Laboratory and clinical aspects of human herpesvirus 6 infections. | journal=Clin Microbiol Rev | year= 2015 | volume= 28 | issue= 2 | pages= 313-35 | pmid=25762531 | doi=10.1128/CMR.00122-14 | pmc=4402955 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25762531 }} </ref> | |||
==Medical therapy== | ==Medical therapy== |
Revision as of 12:03, 25 May 2017
Roseola Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Roseola medical therapy On the Web |
American Roentgen Ray Society Images of Roseola medical therapy |
Risk calculators and risk factors for Roseola medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is no treatment for roseola, however intravenous Foscarnet and ganciclovir are proposed as first line treatment for HHV 6 encephalitis for 3 to 4 weeks.[1]
Medical therapy
The mainstay of therapy for roseola is supportive as HHV 6 typically causes a benign, self limited illness in infants and antiviral therapy is not indicated.
- Supportive therapy for roseola includes antipyretics such as acetaminophen if associated with discomfort
- Rash typically dissappears after 2 days.
References
- ↑ Agut H, Bonnafous P, Gautheret-Dejean A (2015). "Laboratory and clinical aspects of human herpesvirus 6 infections". Clin Microbiol Rev. 28 (2): 313–35. doi:10.1128/CMR.00122-14. PMC 4402955. PMID 25762531.
McInerny, Thomas (2017). American Academy of Pediatrics textbook of pediatric care. Elk Grove Village, IL: American Academy of Pediatrics. ISBN 978-1-58110-966-5.